Carregant...
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies
Since the discovery of the role of proprotein convertase subtilisin kexin 9 (PCSK9) in the regulation of low-density lipoprotein cholesterol (LDL-C) in 2003, a paradigm shift in the treatment of hypercholesterolaemia has occurred. The PCSK9 secreted into the circulation is a major downregulator of t...
Guardat en:
| Publicat a: | Cardiovasc Res |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6383053/ https://ncbi.nlm.nih.gov/pubmed/30629143 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvz003 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|